Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on June 23, 2020. The filing details the entry into a material definitive agreement regarding the company's credit facilities.
Key Financial Metrics and Debt Structure
This filing focuses on debt restructuring rather than operational financial performance. Key terms of the Third Amendment to the Loan and Security Agreement with Pacific Western Bank include:
- Revolving Line of Credit: Reduced from $50.0 million to $30.0 million.
- Maturity Date: Extended to June 23, 2022. This extends to June 23, 2023, if the Company raises at least $125.0 million in equity or strategic partnership proceeds.
- Interest Rate: Increased to the greater of 2.75% above the Prime Rate or 6.00% annually.
- Liquidity Covenant: The Company must maintain unrestricted cash at the Bank of at least $10.0 million.
- Fees:
- Unused line fee: Eliminated.
- Early Termination Fee: Reduced to $600,000.
- Final Payment Fee: 1.00% of the maximum principal amount outstanding.
- Success Fee: $135,000 (if paid by June 30, 2021) or $275,000 (if paid thereafter) upon specific M&A, asset sale, or capital raise events exceeding $50.0 million.
The filing text does not provide current revenue, profit, cash flow, or margin data.
Material Changes
The primary material change is the reduction of available credit capacity from $50.0 million to $30.0 million, coupled with an extension of the maturity date and an increase in the interest rate floor. The removal of the unused line fee and the reduction of the early termination fee represent cost-saving adjustments.
Outlook, Risks, and Contingencies
The agreement introduces specific contingencies tied to future capital raising. The maturity date extension to 2023 is conditional on securing $125.0 million in proceeds. Additionally, the Company faces potential success fees of up to $275,000 if it executes significant equity issuances, debt issuances, or strategic partnerships generating over $50.0 million in gross cash proceeds. The requirement to maintain $10.0 million in unrestricted cash at the lender imposes a liquidity constraint.
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the new $10.0 million unrestricted cash covenant.
- Assess the impact of the reduced $30.0 million credit facility on the Company's operational runway.
- Monitor upcoming capital raise activities to determine if the $125.0 million threshold for the 2023 maturity extension is met.
- Review the impact of the increased interest rate floor (6.00%) on future interest expense.